JP2003530320A5 - - Google Patents

Download PDF

Info

Publication number
JP2003530320A5
JP2003530320A5 JP2001559492A JP2001559492A JP2003530320A5 JP 2003530320 A5 JP2003530320 A5 JP 2003530320A5 JP 2001559492 A JP2001559492 A JP 2001559492A JP 2001559492 A JP2001559492 A JP 2001559492A JP 2003530320 A5 JP2003530320 A5 JP 2003530320A5
Authority
JP
Japan
Prior art keywords
thyroid
botulinum toxin
remedies
drug
neurotoxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001559492A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003530320A (ja
Filing date
Publication date
Priority claimed from US09/504,538 external-priority patent/US6524580B1/en
Application filed filed Critical
Publication of JP2003530320A publication Critical patent/JP2003530320A/ja
Publication of JP2003530320A5 publication Critical patent/JP2003530320A5/ja
Pending legal-status Critical Current

Links

JP2001559492A 2000-02-15 2001-02-15 甲状腺疾患の治療法 Pending JP2003530320A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/504,538 2000-02-15
US09/504,538 US6524580B1 (en) 2000-02-15 2000-02-15 Method for treating thyroid disorders
PCT/US2001/004990 WO2001060396A2 (en) 2000-02-15 2001-02-15 Method for treating thyroid disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012145866A Division JP2012207030A (ja) 2000-02-15 2012-06-28 甲状腺疾患の治療法

Publications (2)

Publication Number Publication Date
JP2003530320A JP2003530320A (ja) 2003-10-14
JP2003530320A5 true JP2003530320A5 (https=) 2008-04-10

Family

ID=24006701

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001559492A Pending JP2003530320A (ja) 2000-02-15 2001-02-15 甲状腺疾患の治療法
JP2012145866A Pending JP2012207030A (ja) 2000-02-15 2012-06-28 甲状腺疾患の治療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012145866A Pending JP2012207030A (ja) 2000-02-15 2012-06-28 甲状腺疾患の治療法

Country Status (10)

Country Link
US (6) US6524580B1 (https=)
EP (1) EP1253933B1 (https=)
JP (2) JP2003530320A (https=)
AR (1) AR027442A1 (https=)
AT (1) ATE245032T1 (https=)
AU (1) AU2001238369A1 (https=)
DE (1) DE60100473T2 (https=)
ES (1) ES2199209T3 (https=)
TW (1) TWI283177B (https=)
WO (1) WO2001060396A2 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1251867A4 (en) 2000-02-04 2004-12-08 Unigene Lab Inc NASAL CALCITON INFORMATION
US6821520B2 (en) * 2000-02-15 2004-11-23 Allergan, Inc. Clostridial toxin therapy for Hashimoto's thyroiditis
US6524580B1 (en) * 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6773711B2 (en) * 2000-02-15 2004-08-10 Allergan, Inc. Botulinum toxin therapy for Hashimoto's thyroiditis
US8563257B2 (en) * 2000-03-30 2013-10-22 Diagnostic Hybrids, Inc. Sensitive and rapid methods of using chimeric receptors to identify autoimmune disease and assess disease severity
US8293879B2 (en) 2000-03-30 2012-10-23 Diagnostic Hybrids, Inc. Methods of using chimeric receptors to identify autoimmune disease
WO2002000172A2 (en) * 2000-06-28 2002-01-03 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals)
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US7178059B2 (en) * 2003-05-07 2007-02-13 Egenera, Inc. Disaster recovery for processing resources using configurable deployment platform
US20040226556A1 (en) * 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US8137924B2 (en) * 2003-12-19 2012-03-20 Wisconsin Alumni Research Foundation Method and compositions for detecting botulinum neurotoxin
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
EP1982997B1 (en) 2004-09-01 2012-08-08 Allergan, Inc. Degradable clostridial toxins
EP1871789B1 (en) 2005-03-15 2013-11-06 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
US8105611B2 (en) * 2005-06-17 2012-01-31 Allergan, Inc. Treatment of autoimmune disorder with a neurotoxin
JP5826450B2 (ja) 2005-07-22 2015-12-02 ザ ファウンドリー， エルエルシー 治療薬の送達のためのシステムおよび方法
US7655243B2 (en) 2005-07-22 2010-02-02 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
US10052465B2 (en) 2005-07-22 2018-08-21 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
US12433837B2 (en) 2005-07-22 2025-10-07 The Foundry, Llc Systems and methods for delivery of a therapeutic agent
US7708699B2 (en) * 2005-11-18 2010-05-04 Daag International, Inc. Reflexometry and hormone function
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
US8088127B2 (en) 2008-05-09 2012-01-03 Innovative Pulmonary Solutions, Inc. Systems, assemblies, and methods for treating a bronchial tree
RU2446791C2 (ru) * 2009-06-18 2012-04-10 Федеральное государственное учреждение "Северо-Западный окружной медицинский центр Минздравсоцразвития" Способ этаноловой склеротерапии кистозно-трансформированных узлов щитовидной железы
AU2010315396B2 (en) 2009-10-27 2016-05-05 Nuvaira, Inc Delivery devices with coolable energy emitting assemblies
JP6000851B2 (ja) 2009-11-11 2016-10-05 ホライラ， インコーポレイテッド 組織治療および狭窄制御のためのシステム、装置、および方法
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US9011323B2 (en) * 2010-10-08 2015-04-21 Invuity, Inc. Method and apparatus for soft tissue retraction
EP2836193B1 (en) 2012-04-13 2018-01-31 Lubrizol Advanced Materials, Inc. Compounds which inhibit neuronal exocytosis (ii)
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
CN107108703B (zh) 2015-01-09 2022-09-23 益普生生物创新有限公司 阳离子神经毒素
US9855317B2 (en) 2015-04-27 2018-01-02 Reflex Medical, Inc. Systems and methods for sympathetic cardiopulmonary neuromodulation
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
WO2018060351A1 (en) 2016-09-29 2018-04-05 Ipsen Biopharm Limited Hybrid neurotoxins
WO2019162696A1 (en) 2018-02-26 2019-08-29 Ipsen Biopharm Limited Use of ultrasound to guide injection of non-cytotoxic protease
DE102019215585B4 (de) * 2019-10-10 2022-02-17 KCM Egészségügyi és Tudományos Korlátolt Felelösségü Társaság Verfahren zur prävention von strahlenschäden in humanen drüsen
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
AU2022252296A1 (en) 2021-03-30 2023-09-21 Tulavi Therapeutics, Inc. Methods and compositions for the ablation of nerves
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022544A (en) 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US5786348A (en) * 1991-01-08 1998-07-28 Bone Care International, Inc. Methods for preparation and use of 1α,24(S)-dihydroxy vitamin D2
ES2107051T3 (es) 1992-09-21 1997-11-16 Upjohn Co Formulaciones de proteinas de liberacion sostenida.
WO1994012158A1 (en) 1992-12-02 1994-06-09 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
EP1099445A3 (en) * 1993-06-10 2001-09-05 Allergan, Inc. Treatment of neuromuscular disorders and conditions with different botulinum serotype
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
ES2332905T3 (es) * 1993-12-28 2010-02-15 Allergan, Inc. Uso del componente neurotoxico de la toxina botulinica para el tratamiento de trastornos de musculos lisos.
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US6007843A (en) 1995-09-29 1999-12-28 Lam Pharmaceuticals Corp. Sustained release delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
EP1011695B2 (en) 1997-07-15 2009-11-04 The Regents of the University of Colorado Use of neurotoxin therapy for treatment of prostate disorders
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US6022554A (en) 1997-12-15 2000-02-08 American Home Products Corporation Polymeric microporous film coated subcutaneous implant
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US6432723B1 (en) * 1999-01-22 2002-08-13 Clinical Micro Sensors, Inc. Biosensors utilizing ligand induced conformation changes
US6358513B1 (en) * 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6524580B1 (en) * 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6649161B1 (en) * 2000-02-22 2003-11-18 Allergan, Inc. Method for treating hypocalcemia
US6432623B1 (en) * 2001-04-27 2002-08-13 Eastman Kodak Company Method for processing a photographic element comprising a simultaneously coated protective overcoat

Similar Documents

Publication Publication Date Title
JP2003530320A5 (https=)
JP2003520822A5 (https=)
JP2003519666A5 (https=)
Marks et al. A double-blind placebo-controlled trial of intranasal capsaicin for cluster headache
US20230105611A1 (en) Combination therapy with cgrp antagonists and clostridial derivatives
Jost et al. Repeat Botulin Toxin Injections in Anal Fissure (In Patients with Relapse and After Insufficient Effect of First Treatment)
CA2218857A1 (en) Clostridial toxin derivatives able to modify peripheral sensory afferent functions
IL165531A0 (en) GLP-1 and methods for treating diabetes
US20180243282A1 (en) Preparation and Use of Combination Enzyme and Gastrointestinal Modulator Delivery Systems
EA200000468A1 (ru) Терапевтическая композиция для введения толтеродина с контролируемым высвобождением
WO1998036728A3 (en) Sustained analgesia achieved with buprenorphine
JP2017081997A (ja) 血管の過敏反応と関連した皮膚状態を治療する方法および組成物
CN102811722A (zh) 用石房蛤毒素衍生物对触觉丧失进行的治疗
WO2002089805A3 (en) Use of regularly scheduled high dose intravenous methotrexate therapy
JP2004501104A5 (https=)
Thomas et al. Use of methadone in a highly tolerant patient receiving parenteral hydromorphone
WO2021005493A1 (en) Cgrp antagonists and botulinum toxins for the treatment of inflammatory and neurologic disorders
DeCHRISTOFORO et al. High-dose morphine infusion complicated by chlorobutanol-induced somnolence
AU707467B2 (en) Nasal administration of agents for treatment of delayed onset emesis
EP0680760A1 (en) Topical antipruritic composition containing a phosphonic acid diester compound
US10959964B2 (en) Use of a sprayable composition comprising ambroxol
WO2024112527A3 (en) Methods for the treatment of thyroid eye disease
Christensen et al. Analgesic effect of intraarticular morphine. A controlled, randomised and double‐blind study
Di Gregorio et al. An alternative to continuous subcutaneous infusion of desferrioxamine in thalassaemic patients
Heinen et al. Dystonic posture of lower extremities associated with myelomeningocele: successful treatment with botulinum A toxin in a six-month-old child